| ID Source | ID |
|---|---|
| PubMed CID | 44143153 |
| CHEMBL ID | 1404277 |
| Synonym |
|---|
| ml096 |
| smr001382691 |
| MLS002460474 , |
| 4-chloranyl-n-(5-methyl-1,3,4-oxadiazol-2-yl)-1,2,3-dithiazol-5-imine |
| (4-chlorodithiazol-5-ylidene)-(5-methyl-1,3,4-oxadiazol-2-yl)amine |
| 4-chloro-n-(5-methyl-1,3,4-oxadiazol-2-yl)-5-dithiazolimine |
| 4-chloro-n-(5-methyl-1,3,4-oxadiazol-2-yl)dithiazol-5-imine |
| cid_44143153 |
| bdbm80343 |
| CHEMBL1404277 |
| Q27164723 |
| GLXC-02693 |
| 1186646-97-8 |
| Class | Description |
|---|---|
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.1313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.4108 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.0323 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 28.1838 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 2.5119 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 19.9526 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| PINK1 | Homo sapiens (human) | Potency | 50.1187 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 6.1304 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720569; AID720584 |
| 67.9K protein | Vaccinia virus | Potency | 4.4668 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| Parkin | Homo sapiens (human) | Potency | 50.1187 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 3.1623 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 1.6834 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 19.9526 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 2.0922 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 6.3096 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 0.5623 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.1623 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 5.3582 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 58.0000 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 12.5000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 12.5000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 69.5700 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 4.6000 | 0.2700 | 26.3638 | 100.0000 | AID504719 |
| DNA dC->dU-editing enzyme APOBEC-3A isoform a | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 1.4800 | 14.5267 | 61.2000 | AID504722 |
| RNA-editing ligase 1, mitochondrial | Trypanosoma brucei brucei | IC50 (µMol) | 79.0000 | 0.4108 | 1.4717 | 3.5100 | AID1117295 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Skn7p | Saccharomyces cerevisiae (brewer's yeast) | AbsAC40_uM | 0.8320 | 0.6600 | 5.2696 | 18.2300 | AID624258 |
| jumonji domain containing 2C, partial | Homo sapiens (human) | AC50 | 6.0570 | 0.4245 | 6.7462 | 15.2100 | AID488835 |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 3.1270 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| HSP40, subfamily A [Plasmodium falciparum 3D7] | Plasmodium falciparum 3D7 | AbsAC1000_uM | 3.2190 | 0.1290 | 4.1169 | 11.3160 | AID540271 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 1.0310 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||